Small Grants Program for Cancer Epidemiology (R03)

Small Grants Program for Cancer Epidemiology (R03) is sponsored by National Institutes of Health (NIH). Supports small-scale research projects in cancer epidemiology to foster new ideas and pilot studies.

Expired PAR-12-039: Small Grants Program for Cancer Epidemiology (R03) This notice has expired. Check the NIH Guide for active opportunities and notices. of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) of Participating Organizations National Cancer Institute ( NCI ) Funding Opportunity Title Small Grants Program for Cancer June 3, 2014 - Notice NOT-14-074 supersedes instructions in Section III. 3 regarding applications that are essentially the same.

May 30, 2013 ( NOT-OD-13-074 ) - NIH to Require Use of Updated Electronic Application Forms for Due Dates on or after September 25, 2013. Forms-C applications are required for due dates on or after September 25, 2013. Funding Opportunity Announcement (FOA) Number Additional Information on Eligibility .

Catalog of Federal Domestic Assistance (CFDA) Number(s) This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of Small Research Grant (R03) applications for research on cancer etiology and epidemiology.

The overarching goal of this FOA is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Open Date (Earliest Submission Date) Letter of Intent Due Date March 19, 2012; July 17, 2012; November 19, 2012; March 19, 2013; July 23, 2013; November 19, 2013; March 18, 2014; July 22, 2014; November 18, 2014, by 5:00 PM local time of applicant organization.

AIDS Application Due Date(s) June/July 2012; October/November 2012; February/March 2013; June/July 2013; October/November 2013; February/March 2014; June/July 2014; October/November 2014; February/March 2015 October 2012; January 2013; May 2013; October 2013; January 2014; May 2014; October 2014; January 2015; May 2015 December 2012; April 2013; July 2013; December 2013; April 2014; July 2014; December 2014; April 2015; July 2015 Required Application Instructions It is critical that applicants follow the instructions in 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV . When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review. Part 1. Overview Information Part 2.

Full Text of the Announcement Section I. Funding Opportunity Description Section II. Award Information Section III.

Eligibility Information Section IV. Application and Submission Section V. Application Review Information Section VI.

Award Administration Information Section VII. Agency Contacts Section VIII. Other Information Full Text of Announcement Section I.

Funding Opportunity Description This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of Small Research Grant (R03) applications for research on cancer etiology and epidemiology.

The overarching goal of this FOA is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Using the NIH Small Research Grant (R03) funding mechanism, this FOA focuses on different types of projects including, but not limited to: (1) pilot and feasibility studies; (2) secondary analysis of existing data; (3) small, self-contained research projects; (4) development of research methodology; and (5) development of new research technology.

The R03 mechanism is critical for collection of pilot data that can be used for larger grant applications such as the Research Project Grant Mechanism (R01). R01 studies in cancer epidemiology usually require large sample sizes, complex logistics, extensive fieldwork, acquisition of biospecimens, and, sometimes, the acquisition of sensitive information such as reproductive histories.

main mission of the Epidemiology and Genetics Research Program ( EGRP ) is to increase our understanding of the determinants of cancer and cancer-related outcomes in human populations.

This mission includes using an epidemiologic approach to facilitate movement of discoveries in the basic sciences and improved technologies to studies in human populations, discoveries about the determinants of cancer and cancer-related health outcomes after cancer into clinical and public health practice, and the movement of scientific knowledge from clinical and public health to human studies and basic biology.

Cancer occurrence is usually measured by development of an incident cancer. Health outcomes after cancer include recurrence, survival, second primary cancers, new health conditions, and mortality.

Determinants of cancer occurrence and health outcomes include behavioral, environmental, infectious, medical, and social and cultural factors and life events and experiences that have a health impact as well as genetic factors and other personal susceptibility factors.

Specific Research Objectives Most cancers are multi-factorial in etiology and require an understanding of how these factors modify and interact with each other in leading to cancer.

Scientific emphasis in this FOA reflects high-priority areas in cancer epidemiology research that have been identified by NCI-coordinated Progress are at least four key areas of research , which include methods and technologies, identification of modifiable risk factors, identification of host susceptibility factors, and clinical and translational epidemiology.

the limits of the scientific scope appropriate for the mechanism of this FOA, specific topics of interest may include, but are not limited to, the following: Methods and Technologies focuses on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility.

Validating measurements in body fluids and tissues of exogenous exposures associated with the development of cancer; Applying epigenetic approaches (including microRNA) in cancer Analyzing existing data that otherwise may have gone unexplored, such as pooled analyses of data from multiple studies coordinated into Exploring relationship between reported tobacco use and actual delivered amounts of tobacco constituents in epidemiologic studies and other large datasets in order to develop standardized markers of exposure in cancer Addressing epidemiologic research issues and translate technological approaches developed in the context of other research endeavors to development of biomarkers of risk susceptibility and to cancer epidemiologic Translating paradigms and findings from basic biological sciences into epidemiologic studies and ensure that epidemiologic findings can be used to identify research directions in the basic sciences; Improving epidemiologic study data collection, study designs, and analysis; Assessing the reliability and validity of methods and technologies for use in epidemiologic studies and ensure that these methods are sufficiently robust to use in epidemiologic data collection settings; Developing technologies to identify new cancer-associated infectious Developing technologies to identify cancer-associated metabolites in epidemiologic studies.

Modifiable Risk Factors focuses on factors that may be modifiable, such as diet and nutrition, alcohol, physical activity and energy balance, tobacco, infectious diseases, physical and chemical agents, and medical exposures including medications and treatments.

Developing novel methods and technologies in risk assessment; Etiology of cancer in human populations relating to factors that may be modifiable such as nutrition, physical activity and energy balance, infectious diseases, and physical and chemical agents Studying differences in cancer susceptibility and risk in individuals and populations and the multiple environmental and genetic factors that jointly contribute to cancer, with the ultimate goal of elucidating the Evaluation of the association of and magnitude of cancer risk associated with biomarkers of exposure, biologically effective dose, and early Development of research resources, infrastructures, and consortia with a focus on modifiable risk factors to facilitate and maximize the scientific potential of cancer epidemiology research.

Host Susceptibility Factors focuses on personal susceptibility factors such as genetic, epigenetic, immunological and hormonal biological pathways, and social, cultural, and race/ethnic factors.

Exploring the etiology of mechanisms related to energy balance and the cancer risk and prognosis; Etiology of cancer in human populations related to host (i.e., personal) susceptibility factors such as genetic, epigenetic, immunological and hormonal biological pathways; and social, cultural, and race/ethnicity factors; Evaluation of the association of and magnitude of cancer risk associated with biomarkers of host susceptibility such as physiological status Clinical and Translational Epidemiology focuses on clinical factors that influence development of cancer among persons with underlying diseases and conditions; the progression, recurrence, and mortality from cancer; and new Planning an epidemiological study to apply validated relevant carcinogenesis markers to better understand the natural history of neoplasms and identify individuals at high risk; Determining applicability of biomarkers of tumor initiation and progression for epidemiologic studies; Epidemiologic studies in survivorship; Developing and validating methods, including statistical applications, to measure dietary components and metabolites in foods and body fluids, in epidemiologic studies; and Developing/improving methodologies to collect epidemiological data via the internet, while maintaining integrity and confidentiality of patient/participant information.

In addition, investigators are encouraged to propose epidemiologic studies using new approaches such as those involving use of circulating DNA, exfoliated cells, haplotype analysis, immunoassays, in silico assays, mass spectrometry, microsatellite assays, and proteomic arrays.

Applicants are encouraged to submit applications to study cancer sites that have previously been traditionally understudied; these include cancers of the esophagus, endometrium, liver, hematopoietic system (especially multiple myeloma), pancreas, testes, and brain.

Investigators are encouraged to validate measurements in body fluids and tissues of exogenous exposures associated with development of cancer using biospecimen repositories from some of the largest epidemiological cohorts supported by the EGRP (see http://epi. grants. cancer.

gov/ResPort/cohorts. html ). Section II.

Award Information Application Types Allowed Glossary and the SF 424 (R&R) Application Guide provide details on Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious A project period of up to two years and a budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 direct costs over two years).

The scope of the proposed project should determine the project period. The maximum period is 2 years. described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Nonprofits without 501(c)(3) IRS Status (Other than Institutions For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Applicant organizations must complete the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award.

Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following Contractor Registration (CCR) must maintain an active registration, to be renewed at least annually All Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization.

All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.

Eligible Individuals (Program Director(s)/Principal Investigator(s)) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.

Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PD(s)/PI(s), visit the Multiple Program Director(s)/Principal Investigator(s) Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) This FOA does not require cost sharing as defined in the NIH Grants Policy Statement . 3.

Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.

Resubmission applications may be submitted, according to the NIH Policy on Resubmission Applications from the SF 424 (R&R) Application Guide. Section IV. Application and Submission Information Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.

gov . 2. Content and Form of Application Submission It is critical that applicants follow the instructions in (R&R) Application Guide , except where instructed in this funding opportunity announcement to do otherwise.

Conformance to the requirements in the Application Guide is required and strictly enforced.

Applications that are out of compliance with these instructions may be delayed or not accepted for For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Required and Optional Components The forms package associated with this FOA includes all applicable components, mandatory and optional.

Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional All page limitations described in the SF424 Application Page Limits must be followed.

PHS 398 Research Plan Component All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies; GWAS) as provided in the SF424 All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide, with the following modification: No publications or other printed material, with the exception of pre-printed questionnaires or surveys, may be included in the Appendix.

Foreign (non-US) institutions must follow policies described Grants Policy Statement , and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide. Part I. Overview Information contains information about Key Dates.

Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission. Organizations must submit applications via Grants. gov , the online portal to find and apply for grants across all Federal agencies.

Applicants must then complete the submission process by tracking the status of the application in the eRA Commons , NIH’s electronic system for grants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission. Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide. 4.

Intergovernmental Review This initiative is not subject to intergovernmental All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Pre-award costs are allowable only as described in the NIH Grants Requirements and Information Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide.

Paper applications will not be accepted. Applicants must complete all required registrations before the application due date. Section III.

Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package .

Failure to register in the Commons and to include a valid PD(s)/PI(s) Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the Central Contractor Registration (CCR).

Additional information may be found in the SF424 (R&R) Application Guide. tips for avoiding common errors. Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH.

Applications that are incomplete will not be reviewed. In order to expedite review, applicants are requested to notify the {IC} Referral Office by email at { [email protected] } when the application has been submitted. Please include the FOA number and title, PD(s)/PI(s) name, and title of the application.

Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115 . Section V. Application Review Information Only the review criteria described below will be considered in the review process.

As part of the NIH mission , all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer For this particular announcement, note the following: The R03 small grant supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding.

Because the research project usually is limited, an R03 grant application may not contain extensive detail or discussion. Accordingly, reviewers should evaluate the conceptual framework and general approach to the problem. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data.

Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?

If the project is collaborative or multi-PD(s)/PI(s), do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions?

Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project?

Are potential problems, alternative strategies, and benchmarks for success presented?

If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed?

Will the project benefit from unique features of the scientific environment, subject populations, or collaborative Additional Review Criteria As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.

Protections for Human Subjects For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to Subjects Protection and Inclusion Guidelines .

Inclusion of Women, Minorities, and When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines .

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia.

For additional information on review of the Vertebrate Animals section, please for Review of the Vertebrate Animal Section . Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project.

If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes Additional Review Considerations As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.

Applications from Foreign Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan ; 2) Sharing Model Organisms ; and 3) Genome Wide Association Studies (GWAS) .

Budget and Period of Support Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NCI, in accordance with NIH peer review policy and procedures , using the stated review criteria . Review assignments will be shown in the eRA Commons.

As part of the scientific peer review, all applications: May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review), will be discussed and assigned an overall impact/priority Will receive a written critique.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board.

The following will be considered in making funding decisions: Scientific and technical merit of the proposed project as determined by scientific peer review. Relevance of the proposed project to program priorities. 3.

Anticipated Announcement After the peer review of the application is completed, the PD(s)/PI(s) will be able to access his or her Summary Statement (written critique) via the eRA Commons .

Information regarding the disposition of applications is available in the NIH Grants Administration Information If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications.

The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official. Awardees must comply with any funding restrictions described in Section IV. 5.

Funding Restrictions . Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk.

These costs may be reimbursed only to the extent considered allowable pre-award costs. Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website. National Policy Requirements All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA.

For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities . More information is Conditions and Information for NIH Grants .

Cooperative Agreement Terms and Conditions of Award When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement .

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.

All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www. fsrs. gov on all subawards over $25,000.

See the NIH Grants Policy Statement for additional information on this reporting Section VII. Agency Contacts We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Application Submission Contacts Customer Support (Questions regarding Grants.

gov registration and submission, downloading or navigating forms) GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources) eRA Commons Help Desk(Questions regarding eRA Commons registration, tracking application status, post submission issues) Phone: 301-402-7469 or 866-504-9552 (Toll Free) Scientific/Research Contact(s) Division of Cancer Control and Population Sciences.

National Cancer Institute (NCI) E-mail: [email protected] Division of Extramural Activities National Cancer Institute E-mail: [email protected] Financial/Grants Management Contact(s) Office of Grants Administration National Cancer Institute E-mail: [email protected] Recently issued trans-NIH policy notices may affect your application submission.

A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts . All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement .

Authority and Regulations Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts